Kalaris Therapeutics (KLRS) Payables (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Payables of $905000.0 for Q1 2026, down 61.88% year-over-year from $2.4 million in Q1 2025, and down 29.35% quarter-over-quarter from $1.3 million in Q4 2025.
Kalaris Therapeutics (KLRS) Payables (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Payables history runs 8 years deep, the most recent figure standing at $905000.0 for Q1 2026.
- In Q1 2026, Payables fell 61.88% year-over-year to $905000.0; the TTM figure through Mar 2026 stood at $905000.0 (down 61.88% YoY), while the FY2025 annual figure was $1.3 million, down 93.93% from the prior year.
- Payables for Q1 2026 stood at $905000.0, down from $1.3 million in the prior quarter.
- The five-year high for Payables was $21.1 million in Q4 2024, with the low at $51000.0 in Q3 2024.
- The 5-year median for Payables is $3.7 million (2025), against an average of $4.0 million.
- The sharpest annual moves came in 2022 and 2024: Payables surged 3575.94% in 2022, then slumped 98.7% in 2024.
- Kalaris Therapeutics' Payables stood at $3.0 million in 2022, then surged by 125.07% to $6.8 million in 2023, then surged by 212.1% to $21.1 million in 2024, then sank by 93.93% to $1.3 million in 2025, then dropped by 29.35% to $905000.0 in 2026.
- Business Quant data shows KLRS's Payables at $905000.0 in Q1 2026, $1.3 million in Q4 2025, and $494000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Kalaris Therapeutics | 97.09 Mn | 97.09 Mn | - | 1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 905,000.00 |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 494,000.00 |
| Jun 30, 2025 | 3.68 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 21.10 Mn |
| Sep 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 765,000.00 |
| Dec 31, 2023 | 6.76 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 5.16 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 4.89 Mn |
| Jun 30, 2022 | 5.52 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 8.36 Mn |
| Sep 30, 2021 | 133,000.00 |